Studies on N3-O-toluyl-flulorouracil (TFu) liposomes

Chinese Pharmaceutical Journal

Volumn 42, Issue 6, 2007, Pages 445-449

  Sun, Wei Tong ^a   Na, Zhang ^a   Li, Ai Guo ^a   Xu, W F ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bioavailability; Liposomes; N3 O toluyl flulorouracil (TFu); Quality evaluation

Indexed keywords

FLUOROURACIL DERIVATIVE; LIPOSOME; N3 O TOLUYLFLUOROURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SYNTHESIS; MOUSE; NONHUMAN; PARTICLE SIZE;

EID: 54549116948     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. LI Q, FENG F Y, HAN J, et al. Phase III clinical study of a new anticancer drug atofluding[J]. Chin J Cancer, 2002,21 (12):1350-1353.
2. YAN M X. The synthesis and preclinical study of mutiple-grade prodrugs of 5-flulorouracil[D]. Shandong University post-graduate dissertation, 2004.
3. FAHR A, HOOGEVEST P V, MAY S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery[J]. Eur J Pharm Sci, 2005,26 (3-4):251-265.
4. ANDRESEN T L, JENSEN S S, JORGENSEN K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release[J]. Prog Lipid Res, 2005, 44(1):68-97.
5. PING Q N. Modern Pharmaceutics [M]. Beijing: Chinese Medicine Science and Technology Publishing Press, 1998:608.
6. AVGOUSTAKIS K, BELETSI A, PANAGI Z. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties[J]. J Controlled Release, 2002,79(1-3):123-135.
7. YANG Y B, TANG Z Q, ZHANG P. The pharmacokinetics of atofluding in cancer patients[J]. Chin J New Drugs, 2004,10(3):196-198.
8. EL-SAMALIGY M S, AFIFI N N, MAHMOUD E A. Increasing bioavailability of silymarin using a buccal liposomal delivery system: Preparation and experimental design investigation[J]. Int J Pharm, 2006,308(1-2):140-148.